|
1
|
Roodman GD: Advances in bone biology: the
osteoclast. Endocr Rev. 17:308–332. 1996.PubMed/NCBI
|
|
2
|
Nair SP, Meghji S, Wilson M, Reddi K,
White P and Henderson B: Bacterially induced bone destruction:
mechanisms and misconceptions. Infect Immun. 64:2371–2380.
1996.PubMed/NCBI
|
|
3
|
Dinarello CA: Biologic basis for
interleukin-1 in disease. Blood. 87:2095–2147. 1996.PubMed/NCBI
|
|
4
|
Nakae S, Asano M, Horai R and Iwakura Y:
Interleukin-1 beta, but not interleukin-1 alpha, is required for
T-cell-dependent antibody production. Immunology. 104:402–409.
2001. View Article : Google Scholar
|
|
5
|
Garlanda C, Dinarello CA and Mantovani A:
The interleukin-1 family: back to the future. Immunity.
39:1003–1018. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Stashenko P, Dewhirst FE, Rooney ML,
Desjardins LA and Heeley JD: Interleukin-1 beta is a potent
inhibitor of bone formation in vitro. J Bone Miner Res. 2:559–565.
1987. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ohmori Y, Hanazawa S, Amano S, Hirose K,
Kumegawa M and Kitano S: Effects of recombinant human interleukin I
alpha and interleukin 1 beta on cell growth and alkaline
phosphatase of the mouse osteoblastic cell line MC3T3-E1. Biochim
Biophys Acta. 970:22–30. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lacey DL, Grosso LE, Moser SA, Erdmann J,
Tan HL, Pacifici R and Villareal DT: IL-1-induced murine osteoblast
IL-6 production is mediated by the type 1 IL-1 receptor and is
increased by 1,25 dihydroxyvitamin D3. J Clin Invest. 91:1731–1742.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lee YM, Fujikado N, Manaka H, Yasuda H and
Iwakura Y: IL-1 plays an important role in the bone metabolism
under physiological conditions. Int Immunol. 22:805–816. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gowen M, Wood DD, Ihrie EJ, McGuire MK and
Russell RG: An interleukin 1-like factor stimulates bone resorption
in vitro. Nature. 306:378–380. 1983. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lorenzo JA, Sousa SL, Alander C, Raisz LG
and Dinarello CA: Comparison of the bone-resorbing activity in the
supernatants from phytohemagglutinin-stimulated human peripheral
blood mononuclear cells with that of cytokines through the use of
an antiserum to interleukin 1. Endocrinology. 121:1164–1170. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nakamura I and Jimi E: Regulation of
osteoclast differentiation and function by interleukin-1. Vitam
Horm. 74:357–370. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Matsuguchi T, Chiba N, Bandow K, Kakimoto
K, Masuda A and Ohnishi T: JNK activity is essential for Atf4
expression and late-stage osteoblast differentiation. J Bone Miner
Res. 24:398–410. 2009. View Article : Google Scholar
|
|
14
|
Guo C, Yuan L, Wang JG, Wang F, Yang XK,
Zhang FH, Song JL, Ma XY, Cheng Q and Song GH: Lipopolysaccharide
(LPS) induces the apoptosis and inhibits osteoblast differentiation
through JNK pathway in MC3T3-E1 cells. Inflammation. 37:621–631.
2014. View Article : Google Scholar
|
|
15
|
Guo C, Wang SL, Xu ST, Wang JG and Song
GH: SP600125 reduces lipopolysaccharide-induced apoptosis and
restores the early-stage differentiation of osteoblasts inhibited
by LPS through the MAPK pathway in MC3T3-E1 cells. Int J Mol Med.
35:1427–1434. 2015.PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
17
|
Komori T and Kishimoto T: Cbfa1 in bone
development. Curr Opin Genet Dev. 8:494–499. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Komori T, Yagi H, Nomura S, Yamaguchi A,
Sasaki K, Deguchi K, Shimizu Y, Bronson RT, Gao YH, Inada M, et al:
Targeted disruption of Cbfa1 results in a complete lack of bone
formation owing to maturational arrest of osteoblasts. Cell.
89:755–764. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nakashima K, Zhou X, Kunkel G, Zhang Z,
Deng JM, Behringer RR and de Crombrugghe B: The novel zinc
finger-containing transcription factor osterix is required for
osteoblast differentiation and bone formation. Cell. 108:17–29.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fu H, Doll B, McNelis T and Hollinger JO:
Osteoblast differentiation in vitro and in vivo promoted by
Osterix. J Biomed Mater Res A. 83:770–778. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim HK, Cho SG, Kim JH, Doan TK, Hu QS,
Ulhaq R, Song EK and Yoon TR: Mevinolin enhances osteogenic genes
(ALP, type I collagen and osteocalcin), CD44, CD47 and CD51
expression during osteogenic differentiation. Life Sci. 84:290–295.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pearson G, Robinson F, Beers Gibson T, Xu
BE, Karandikar M, Berman K and Cobb MH: Mitogen-activated protein
(MAP) kinase pathways: regulation and physiological functions.
Endocr Rev. 22:153–183. 2001.PubMed/NCBI
|
|
23
|
Kyriakis JM and Avruch J: Mammalian MAPK
signal transduction pathways activated by stress and inflammation:
a 10-year update. Physiol Rev. 92:689–737. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xia Z, Dickens M, Raingeaud J, Davis RJ
and Greenberg ME: Opposing effects of ERK and JNK-p38 MAP kinases
on apoptosis. Science. 270:1326–1331. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tang C, Liang J, Qian J, Jin L, Du M, Li M
and Li D: Opposing role of JNK-p38 kinase and ERK1/2 in hydrogen
peroxide-induced oxidative damage of human trophoblast-like JEG-3
cells. Int J Clin Exp Pathol. 7:959–968. 2014.PubMed/NCBI
|
|
26
|
Fister S, Günthert AR, Aicher B, Paulini
KW, Emons G and Gründker C: GnRH-II antagonists induce apoptosis in
human endometrial, ovarian, and breast cancer cells via activation
of stress-induced MAPKs p38 and JNK and proapoptotic protein Bax.
Cancer Res. 69:6473–6481. 2009. View Article : Google Scholar : PubMed/NCBI
|
